Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1643 1644
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18289836 | Targeting Extracellular Matrix Proteins to Regulate NK Cell Function in Peripheral Tissues | Non-Final OA | The General Hospital Corporation |
| 18404727 | ANTI-FIBROTIC TISSUE RESIDENT MEMORY T CELLS AND USES THEREOF | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18350637 | IGM-MULTIMERIZED SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1 | Non-Final OA | Fred Hutchinson Cancer Center |
| 18573370 | EFPEGLENATIDE TO REDUCE RISK OF DEVELOPING CARDIOVASCULAR DISEASE OR RENAL DYSFUNCTION | Non-Final OA | HANMI PHARM. CO., LTD. |
| 18285511 | MULTI-SPECIFIC ANTIBODY TARGETING BCMA | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy